NeoTherma Oncology news
NeoTherma Oncology (NTO) announces they have expanded their leadership team with key senior staff who will advance the development and commercialization of the VectRx System. NTO’s new additions include:
- Ken Belt, Chief Engineer: Ken will lead RF design, and has 48 years of experience in the medical device field with extensive experience in MRI coil and phased array engineering.
- Lawson Fisher
NeoTherma Oncology, having achieved both FDA approval for its Investigational Device Exemption for an Early Feasibility Study of the VectRx™ System and institutional review board approval at an east coast National Cancer Institute-designated Cancer Center, has initiated recruitment for a first-in-human trial in patients with pancreatic cancer.
Neotherma Oncology (NTO) announces the appointment of Bob Larson as Chief Executive Officer effective immediately. Bob is an experienced health care executive with 30+ years spread across the medical device, bio-pharmaceutical, and tech industries. He has held senior leadership positions at companies ranging from startups to Fortune 500 multi-nationals such as Johnson & Johnson and Zoetis.
NeoTherma Oncology, (NTO) a privately held medical device company developing novel non-invasive treatments for solid tumors, today announces they have submitted an Investigational Device Exemption (IDE) application to the Food and Drug Administration (FDA) to initiate First-in-Human (FiH) studies of the VectRx™ System in patients with pancreatic cancer being treated with standard of care chemotherapy under the Early Feasibility Study (EFS) Guidance. Previously granted `Breakthrough Tech
NeoTherma Oncology (NTO), developer of an advanced bioelectric medical device for noninvasive treatment of serious cancers, today announced the Company was recently awarded Small Business Innovation Research grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH). This Phase I award provides resources to enable `Quantifiable Thermal Therapy Using Magnetic Resonance Thermometry Imaging`. Under terms of the grant, NTO will work closely with researchers from the
NeoTherma Oncology (NTO), developer of an advanced bioelectric medical device for noninvasive treatment of serious cancers, today announced the closing of a $6 million capital raise. The financing provides the resources to conduct human testing of NTO`s VectRx™ thermal oncology treatment platform, designated by FDA as a `Breakthrough Therapy` for Pancreatic Cancer, expediting patient access to this novel adjuvant therapy[1]. The Series A convertible note raise was co-led by a current in
NeoTherma Oncology, (NTO) a privately held medical device company developing novel non-invasive treatments for solid tumors, reported the results of a pre-clinical porcine study that demonstrated the safe and effective heating of the pancreas with a prototype version of its Vectron TTx device.
Key Findings and Conclusions:
- Safety demonstrated by the absence of injury to skin, internal organs or blood chemistries from repeated thermal treatments in a preclinical animal m
NeoTherma Oncology, (NTO) a privately held medical device company developing novel non-invasive treatments for solid tumors, today announces that the United States Food and Drug Administration (FDA) has granted the company`s petition to admit its Vectron TTx treatment for Pancreatic Cancer as Breakthrough Device under FDA`s Expedited Access Pathway (EAP).
Signed by President Obama in December 2016, the 21st Century Cures Act added a new section (515C) to the Food Drug and Cosmetics Ac